Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
KTRA | US
-0.01
-6.31%
Healthcare
Biotechnology
30/09/2024
17/10/2024
7.54
0.24
0.24
0.20
Kintara Therapeutics Inc. a clinical stage drug development company focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage Phase III-ready therapeutics including VAL-083 a DNA-targeting agent for the treatment of drug-resistant solid tumors such as glioblastoma multiforme as well as other solid tumors including ovarian cancer non-small cell lung cancer and diffuse intrinsic pontine glioma; and REM-001 a late stage photodynamic therapy for the treatment of cutaneous metastatic breast cancer basal cell carcinoma nevus syndrome and access graft failure in hemodialysis patients. Kintara Therapeutics Inc. has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals Inc. and changed its name to Kintara Therapeutics Inc. in August 2020. Kintara Therapeutics Inc. was incorporated in 2009 and is headquartered in San Diego California.
View LessPositive Momentum
High Short-term Volatility
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
125.5%1 month
122.0%3 months
102.6%6 months
144.5%-
-
7.81
-
-
-1.37
-
-
-8.40M
419.63M
419.63M
-
-
-
-
-370.77
1.14
9.81
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.07
Range1M
0.08
Range3M
0.13
Rel. volume
0.73
Price X volume
27.90M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
MeiraGTx Holdings plc | MGTX | Biotechnology | 5.94 | 458.47M | 0.34% | n/a | 109.40% |
Absci Corporation Common Stock | ABSI | Biotechnology | 4.02 | 456.50M | -2.66% | n/a | 6.02% |
Corvus Pharmaceuticals Inc | CRVS | Biotechnology | 7.21 | 450.99M | -1.90% | n/a | 1.37% |
C4 Therapeutics Inc | CCCC | Biotechnology | 6.41 | 444.46M | -8.43% | n/a | 27.69% |
Sage Therapeutics Inc | SAGE | Biotechnology | 7.21 | 440.17M | -0.83% | n/a | 0.22% |
4D Molecular Therapeutics Inc | FDMT | Biotechnology | 8.45 | 439.14M | -2.42% | n/a | 2.32% |
Foghorn Therapeutics Inc | FHTX | Biotechnology | 7.74 | 428.24M | -4.56% | n/a | -285.69% |
Theravance Biopharma Inc | TBPH | Biotechnology | 8.62 | 421.71M | -0.92% | n/a | 24.09% |
GH Research PLC Ordinary Shares | GHRS | Biotechnology | 8 | 416.22M | 3.36% | n/a | 0.38% |
Taysha Gene Therapies Inc | TSHA | Biotechnology | 2.03 | 416.03M | 0.00% | n/a | 53.02% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Lincoln Educational Services Corporation | LINC | Building Products & Equipment | 12.9 | 406.03M | -1.07% | 48.16 | 88.92% |
ONEWATER MARINE INC. | ONEW | Recreational Vehicles | 22.97 | 356.20M | -1.42% | n/a | 286.96% |
Marine Products Corporation | MPX | Recreational Vehicles | 9.77 | 339.19M | -1.11% | 13.34 | 0.00% |
MCBC Holdings Inc | MCFT | Recreational Vehicles | 17.46 | 289.97M | -0.17% | 33.67 | 26.82% |
CPI Card Group Inc | PMTS | Building Products & Equipment | 23.68 | 264.21M | -1.70% | 15.72 | -621.78% |
REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 7.9 | 147.04M | -1.25% | n/a | 58.43% |
Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 32.05 | 92.04M | -1.35% | 5.27 | 19.82% |
Saga Communications Inc | SGA | Broadcasting - Radio | 14.35 | 89.85M | 0.07% | 14.47 | 7.10% |
Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 12.6 | 19.19M | 0.80% | n/a | 204.46% |
ILAG | ILAG | Building Products & Equipment | 0.98 | 17.70M | -3.92% | n/a | 5.48% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -1.37 | 0.53 | Cheaper |
Ent. to Revenue | - | 3,967.00 | - |
PE Ratio | - | 41.03 | - |
Price to Book | 7.81 | 15.55 | Cheaper |
Dividend Yield | - | 2.20 | - |
Std. Deviation (3M) | 102.62 | 72.80 | Riskier |
Debt to Equity | - | -1.23 | - |
Debt to Assets | - | 0.25 | - |
Market Cap | 419.63M | 3.66B | Emerging |